Everolimus Reverses Palbociclib Resistance in ER+ Human Breast Cancer Cells by Inhibiting Phosphatidylinositol 3-Kinase(PI3K)/Akt/Mammalian Target of Rapamycin (mTOR) Pathway

BACKGROUND: Palbociclib, a specific inhibitor of CDK4/6, has been shown to provide a survival benefit in hormone receptor-positive advanced breast cancer; however, its resistance and related mechanisms are unclear. MATERIAL/METHODS: In this study, we constructed palbociclib-resistant hormone recepto...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Lin, Yang, Guangsheng, Dong, Hongming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2019
Materias:
Lab/In Vitro Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327776/
https://www.ncbi.nlm.nih.gov/pubmed/30605443
http://dx.doi.org/10.12659/MSM.912929

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327776/
https://www.ncbi.nlm.nih.gov/pubmed/30605443
http://dx.doi.org/10.12659/MSM.912929

Ejemplares similares